NASDAQ$RGNX

REGENXBIO Inc · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

RGNX Q2 2024 — $2.0M revenue

Securities and Exchange Commission (the SEC) for additional discussion of the risks, uncertainties, assumptions and other important factors that could cause our actual results or developments to diffe. REGENXBIO Inc reported Q2 2024 results. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Revenue: $2.0M.
  • Operating income: $56K.
  • Filed on Form 10-Q (accession 0000950170-24-089320).

Headline financials

Total Revenue

$22.3M

Previous: $20M+11.6%
EPS

-$1.05

Previous: -$1.66+36.7%
Capital Expenditures

-$1.03M

Previous: -$7.4M+86.1%
Free Cash Flow

-$54M

Previous: -$79.5M+32.0%
Net Income

-$53M

Previous: -$72.1M+26.5%
Operating Income

-$56M

Previous: -$73.1M+23.4%
Gross Profit

$11.7M

Previous: $10.5M+11.6%
R&D Expense

$44.8M

No prior period
Stock-Based Comp

$9.44M

Previous: $10.5M-10.2%

Revenue & EPS history

REGENXBIO · Revenue · Quarterly

$22.3M

Q2 2024+11.6%vs Q2 2023
Beat estimate in 3 of 14 quarters(21%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

+0.8%

Avg return

Earnings day

+2.8%

Avg return

5 days after

+1.7%

Avg return

30 days after

57%

24 / 42 earnings

Positive

+28.0%

Q4 2017

Best reaction

-37.8%

Q1 2026

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-37.8%-43.8%-33.8%
Q4 2025-4.7%+8.3%-6.7%
Q3 2025-3.6%-0.5%+13.4%
Q1 2025+2.9%+11.5%+28.0%
Q4 2024+2.6%+29.8%-10.1%
Q3 2024+25.4%+29.6%+7.4%
Q2 2024-8.5%-10.9%-14.2%
Q1 2024-7.5%-7.2%-17.0%
Q4 2023+8.5%+15.5%+14.9%
Q3 2023+2.3%+7.9%+19.1%
Q2 2023-8.7%-8.4%-5.3%
Q1 2023+2.2%-5.3%+1.2%
Q4 2022+10.0%+11.2%-17.6%
Q3 2022-14.5%-14.2%+0.1%
Q2 2022+9.2%+9.4%-6.9%
Q1 2022-14.2%-29.1%-19.1%
Q4 2021+11.1%+5.3%+26.6%
Q3 2021+4.4%+8.0%-12.5%
Q2 2021+0.1%+0.4%+6.9%
Q1 2021+4.8%+8.8%+7.4%
Q4 2020+1.0%-2.4%-16.6%
Q3 2020+1.1%+15.0%+32.0%
Q2 2020-3.4%-2.5%-16.9%
Q1 2020-5.5%-2.0%-9.5%
Q4 2019-14.8%-15.8%-28.7%
Q3 2019-2.6%+7.5%+17.3%
Q2 2019+0.6%-8.5%-22.5%
Q1 2019-12.8%-12.5%-11.7%
Q4 2018-2.2%+7.0%+8.3%
Q3 2018-1.0%-10.0%-24.7%
Q2 2018-5.8%-6.6%+4.4%
Q1 2018+13.2%+24.0%+42.8%
Q4 2017+28.0%+22.9%-3.4%
Q3 2017+0.9%+0.9%+19.6%
Q2 2017+11.8%+12.4%+33.3%
Q1 2017-4.9%+0.8%+9.5%
Q4 2016+6.6%+2.5%-10.2%
Q3 2016+24.6%+28.5%+20.7%
Q2 2016+0.8%+21.3%+41.5%
Q1 2016-3.6%
Q4 2015+1.8%
Q3 2015+14.0%
Q2 2015
Q1 2015
Q4 2014
Q3 2014
Q2 2014
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro